A Double-Blind, Placebo-Controlled Trial of Nefazodone in the Treatment of Patients Hospitalized for Major Depression

Abstract

Nefazodone was superior to placebo in the treatment of marked to severe major depression in patients requiring hospitalization. The clinical benefit of nefazodone was evident as early as the first week of treatment as judged by several measures of efficacy, with significant differences from placebo sustained throughout the trial.